Zhejiang CONBA PharmaceuticalLtd Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Guoliang Luo

Amministratore delegato

CN¥2.0m

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	0.004%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	less than a year

Aggiornamenti recenti sulla gestione

Recent updates

Zhejiang CONBA PharmaceuticalLtd's (SHSE:600572) Problems Go Beyond Weak Profit

Nov 05

It's A Story Of Risk Vs Reward With Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572)

Sep 30

Is Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Using Too Much Debt?

Sep 12

Is Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) Worth CN¥4.3 Based On Its Intrinsic Value?

Aug 20

Here's Why Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Can Manage Its Debt Responsibly

May 21

AMMINISTRATORE DELEGATO

Guoliang Luo (61 yo)

no data

Mandato

CN¥1,978,800

Compensazione

Mr. Guoliang Luo serves as President and Director at Zhejiang CONBA Pharmaceutical Co.,Ltd.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Guoliang Luo	President & Director	no data	CN¥1.98m	0.0040% CN¥ 494.0k
Ming Chen	VP, CFO & Director	no data	CN¥1.29m	0.00040% CN¥ 49.5k
Jianfeng Ye	VP & Director	less than a year	Nessun dato	0.0020% CN¥ 246.4k
Jiqiang Hu	Chairman of the Board	13.6yrs	CN¥2.04m	4.09% CN¥ 506.7m
Shishui Yin	Supervisory Board Chairman	3.2yrs	Nessun dato	0.00040% CN¥ 49.5k
Zuojun Dong	Independent Director	no data	CN¥120.00k	Nessun dato
En Liu	Independent Director	no data	CN¥120.00k	Nessun dato
Yongjiang Wu	Independent Director	no data	CN¥120.00k	Nessun dato
Yang Wang	Director	no data	Nessun dato	Nessun dato
Jiuqin Lu	Independent Director	no data	CN¥120.00k	Nessun dato
Yi Jiang	Co-Chairman of Board	less than a year	Nessun dato	Nessun dato
Qian Jiang	Director	less than a year	Nessun dato	Nessun dato

0.8yrs

Durata media

52yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 600572 non è considerato esperto (durata media del mandato 0.8 anni), il che suggerisce un nuovo consiglio.

Zhejiang CONBA PharmaceuticalLtd Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Zhejiang CONBA Pharmaceutical Co.,Ltd., Annual General Meeting, May 10, 2024

Less than half of directors are independent

Recent updates

Zhejiang CONBA PharmaceuticalLtd's (SHSE:600572) Problems Go Beyond Weak Profit

New minor risk - Earnings quality

Third quarter 2024 earnings released: EPS: CN¥0.055 (vs CN¥0.042 in 3Q 2023)

Now 22% overvalued after recent price rise

It's A Story Of Risk Vs Reward With Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572)

Zhejiang CONBA Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 21%

Now 22% overvalued after recent price rise

Is Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Using Too Much Debt?

Second quarter 2024 earnings released: EPS: CN¥0.066 (vs CN¥0.091 in 2Q 2023)

Is Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) Worth CN¥4.3 Based On Its Intrinsic Value?

Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) agreed to acquire 20.16% stake in Zhejiang Conba Chinese Traditional Medicine Co., Ltd. from Jiyi (Deqing) Enterprise Management Partnership (Limited Partnership) and Xu Jianhong for approximately CNY 310 million.

Zhejiang CONBA Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Dividend increased to CN¥0.20

Here's Why Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Can Manage Its Debt Responsibly

Zhejiang CONBA Pharmaceutical Co.,Ltd., Annual General Meeting, May 10, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zhejiang CONBA Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) announces an Equity Buyback for CNY 400 million worth of its shares.

Zhejiang CONBA Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Zhejiang CONBA Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 17%

Zhejiang CONBA Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 18, 2023

New minor risk - Share price stability

Full year 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.78 in FY 2021)

Investor sentiment improves as stock rises 15%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.008 (vs CN¥0.012 loss in 3Q 2021)

Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) signed the equity transfer agreement to acquire Zhejiang Autuokang Pharmaceutical Technology Co., Ltd. from Zhejiang Autuokang Pharmaceutical Group Co., Ltd for CNY 35.58 million.

Second quarter 2022 earnings released: EPS: CN¥0.041 (vs CN¥0.073 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2021 earnings released: EPS CN¥0.073 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.02 (vs CN¥0.071 in 1Q 2020)

New 90-day low: CN¥4.30

New 90-day low: CN¥4.48

New 90-day low: CN¥4.82

Zhejiang CONBA Pharmaceutical Co.,Ltd.(XSSC:600572) dropped from FTSE All-World Index (USD)

New 90-day low: CN¥5.15

New 90-day low: CN¥5.21

New 90-day low - CN¥5.39

Zhejiang Traditional Chinese Medicine & Health Industry Group Co., Ltd. completed the acquisition of 20% stake in Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) Zhejiang CONBA Group Co., Ltd.